ReviewFrontiers in oncology2024

Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy.

Binsah George et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.